Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials

Daisuke Yabe, Anu Ambos, Bertrand Cariou, Lea Duvnjak, Marc Evans, Guillermo González-Gálvez, Jay Lin, Elena V. Nikonova, Pedro de Pablos-Velasco, Jean François Yale, Bo Ahrén

Research output: Contribution to journalArticlepeer-review


Aims: To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). Materials and methods: In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20. μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index. Results: Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), -0.99 (-10.8), -0.87 (-9.5), -0.86 (-9.4), -0.83 (-9.1); and postprandial plasma glucose (PPG; mmol/L), -7.9, -5.6, -5.5, -4.3 (overall effect . P .

Original languageEnglish
Pages (from-to)1385–1392
JournalJournal of Diabetes and its Complications
Issue number7
Early online date2016 Feb 18
Publication statusPublished - 2016 Oct

Subject classification (UKÄ)

  • Hematology
  • Endocrinology and Diabetes

Free keywords

  • Antidiabetic drug
  • Beta cell
  • GLP-1 analog
  • Glycemic control
  • Type 2 diabetes

Cite this